1,721,002 research outputs found
Potentiation of the antitumor acitivity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with epidermal growth factor receptor tyrosine kinase inhibitors in human cancer cell lines.
No full textThe proteasome is involved in the housekeeping of cellular proteins. It also plays a pivotal role in the turnover of several regulatory proteins, including key intracellular transduction molecules which are induced by activated cell membrane growth factor receptors. Cancer cells are more sensitive than normal cells to proteasome inhibition, indicating that the proteasome could be a valuable target for cancer therapy. In this study, we tested the effect of bortezomib (Velcade®), a specific proteasome inhibitor, alone and in combination with gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), with ZD6474, a dual EGFR and vascular endothelial growth factor TKI and with cetuximab, a blocking anti-EGFR chimeric human-mouse monoclonal antibody. The antiproliferative activity of bortezomib alone (range doses 0.1nM - 100 nM) and in combination with the three EGFR-TKIs was evaluated in human lung (A549, GLC-82, Calu3), colon (GEO, HCT-15, HCT-116, HT-29), pancreatic (MiaPaca2), and esophageal (KYSE-30) cancer cell lines containing functional TGF-EGFR autocrine pathway, by using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and soft agar colony formation assays. Combination effects were analyzed according to the Chou and Talalay method. Cell cycle distribution and apoptosis were quantified by flow cytometry in A549, Calu-3, HCT15, HCT116, after 6 h, 12 h, 24 h and 48 h of treatment with bortezomib (25 nM), alone and in combination with ZD6474 (0.5μM) and cetuximab (1μg/ml). Effects on protein expression were evaluated using western blotting techniques in the same cell lines, after 24 h of treatment with bortezomib alone and in combination with ZD6474 and cetuximab at the same doses. Bortezomib determined a dose-dependent growth inhibition in the nine-cancer cell line panel (IC50 values, range 6-42 nM), showing a significant synergistic antiproliferative effect alone and in combination with either gefitinib, cetuximab, or ZD6474 (Combination Index values, range 0.10-0.55). This effect was accompanied by a significant induction in apoptosis by the combined treatment in the four treated cancer cell lines. Western blot analyses demonstrated that in HCT-116 cell line bortezomib induced a reduction of total and phosphorylated (P)-EGFR expression, and an increase of P-MAPK and p27 expression, without changes of total and P-Akt, MAPK, Bcl-2, Bcl-xL, and p21 expression. In contrast, the combined treatment with bortezomib and each EGFR inhibitor caused an efficient suppression of P-EGFR, P-MAPK and P-Akt levels with a parallel significant increase of p27 protein expression. Our results provide the rationale to test the combination of a proteasome inhibitor with an EGFR-TKI in vivo experiments as multitargeted therapy for human cancers
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
- …
